Charles Schwab
CRBP icon

Charles Schwab’s Corbus Pharmaceuticals CRBP Stock Holding History

Charles Schwab’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$520K Buy
+55,455
New +$525K ﹤0.01% 3226
2025
Q3 		– Sell
-68,148
Closed -$470K – 3479
2025
Q2 		$470K Sell
68,148
-20,377
-23% -$148K ﹤0.01% 3161
2025
Q1 		$470K Sell
88,525
-9,357
-10% -$82.6K ﹤0.01% 3098
2024
Q4 		$1.16M Buy
97,882
+4,239
+5% +$71.1K ﹤0.01% 2862
2024
Q3 		$1.93M Buy
93,643
+64,800
+225% +$3.32M ﹤0.01% 2717
2024
Q2 		$1.31M Buy
+28,843
New +$1.21M ﹤0.01% 2836
2023
Q1 		– Sell
-3,314
Closed -$11K – 3558
2022
Q4 		$11K Hold
3,314
– – ﹤0.01% 3526
2022
Q3 		$17K Hold
3,314
– – ﹤0.01% 3489
2022
Q2 		$26K Buy
+3,314
New +$32K ﹤0.01% 3499
2022
Q1 		– Sell
-1,499
Closed -$28K – 3591
2021
Q4 		$28K Hold
1,499
– – ﹤0.01% 3555
2021
Q3 		$46K Sell
1,499
-15,668
-91% -$618K ﹤0.01% 3462
2021
Q2 		$943K Sell
17,167
-79
-0.5% -$4.38K ﹤0.01% 2950
2021
Q1 		$1.02M Buy
17,246
+2,345
+16% +$154K ﹤0.01% 2852
2020
Q4 		$559K Sell
14,901
-1,123
-7% -$42K ﹤0.01% 2950
2020
Q3 		$866K Buy
16,024
+10,530
+192% +$1.91M ﹤0.01% 2710
2020
Q2 		$1.38M Sell
5,494
-119
-2% -$24K ﹤0.01% 2544
2020
Q1 		$883K Buy
5,613
+393
+8% +$66.4K ﹤0.01% 2527
2019
Q4 		$856K Buy
5,220
+639
+14% +$94.4K ﹤0.01% 2648
2019
Q3 		$670K Hold
4,581
– – ﹤0.01% 2691
2019
Q2 		$953K Buy
4,581
+444
+11% +$95.1K ﹤0.01% 2589
2019
Q1 		$863K Buy
4,137
+525
+15% +$116K ﹤0.01% 2597
2018
Q4 		$633K Sell
3,612
-40
-1% -$7.98K ﹤0.01% 2681
2018
Q3 		$828K Hold
3,652
– – ﹤0.01% 2676
2018
Q2 		$554K Buy
3,652
+423
+13% +$76.9K ﹤0.01% 2773
2018
Q1 		$591K Hold
3,229
– – ﹤0.01% 2688
2017
Q4 		$688K Buy
3,229
+752
+30% +$161K ﹤0.01% 2636
2017
Q3 		$532K Hold
2,477
– – ﹤0.01% 2702
2017
Q2 		$469K Buy
+2,477
New +$486K ﹤0.01% 2716

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Charles Schwab's CRBP Position: Q2 2026 in Review

Charles Schwab opened a new position in Corbus Pharmaceuticals (CRBP) in Q2 2026: 55,455 shares worth $520K. The stake represents ﹤0.01% of the portfolio and ranks #3226 among its holdings. This is a return to the name: Charles Schwab previously reported a position in CRBP as recently as Q2 2025.

Charles Schwab first reported a position in CRBP in Q2 2017 and has held it in 28 quarters since. The position peaked at $1.93M in Q3 2024. 107 funds tracked by Wall St. Rank hold CRBP as of Q2 2026.

  • Charles Schwab held 55,455 shares of Corbus Pharmaceuticals worth $520K as of Q2 2026.
  • Corbus Pharmaceuticals was a new Charles Schwab position in Q2 2026.
  • Corbus Pharmaceuticals made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #3226 holding.
  • Charles Schwab first reported a position in Corbus Pharmaceuticals in Q2 2017 and has held it in 28 quarters since.
  • Charles Schwab's Corbus Pharmaceuticals position peaked at $1.93M in Q3 2024.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.